Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012, Article ID 236401, 6 pages
http://dx.doi.org/10.1100/2012/236401
Clinical Study

Visualization of Chronic Myocardial Infarction Using the Intravascular Contrast Agent MS-325 (Gadofosveset) in Patients

1Department of Internal Medicine/Cardiology, German Heart Institute Berlin, 13353 Berlin, Germany
2Philips Healthcare, 20099 Hamburg, Germany
3Division of Imaging Sciences and Medical Engineering, Department of Cardiovascular Imaging, King's College London, London 5E1 7EH, UK

Received 2 September 2011; Accepted 31 October 2011

Academic Editors: A. Cuocolo and K. Natsis

Copyright © 2012 Thomas Thouet et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. J. Parmelee, R. C. Walovitch, H. S. Ouellet, and R. B. Lauffer, “Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging,” Investigative Radiology, vol. 32, no. 12, pp. 741–747, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. R. B. Lauffer, D. J. Parmelee, H. S. Ouellet et al., “MS-325: a small-molecule vascular imaging agent for magnetic resonance imaging,” Academic Radiology, vol. 3, supplement 2, pp. S356–S358, 1996. View at Google Scholar · View at Scopus
  3. R. B. Lauffer, D. J. Parmelee, S. U. Dunham et al., “MS-325: albumin-targeted contrast agent for MR angiography,” Radiology, vol. 207, no. 2, pp. 529–538, 1998. View at Google Scholar · View at Scopus
  4. T. M. Grist, F. R. Korosec, D. C. Peters et al., “Steady-state and dynamic MR angiography with MS-325: initial experience in humans,” Radiology, vol. 207, no. 2, pp. 539–544, 1998. View at Google Scholar · View at Scopus
  5. D. A. Bluemke, A. E. Stillman, K. G. Bis et al., “Carotid MR angiography: phase II study of safety and efficacy for MS-3251,” Radiology, vol. 219, no. 1, pp. 114–122, 2001. View at Google Scholar · View at Scopus
  6. M. B. Hofman, K. Adzamli, J. S. Allen et al., “Kinetics of a novel blood pool agent (MP-2269) with persistent high relaxivity for MR angiography,” Academic Radiology, vol. 5, supplement 1, pp. S206–S209, 1998. View at Google Scholar · View at Scopus
  7. S. Kelle, T. Thouet, T. Tangcharoen et al., “Whole-heart coronary magnetic resonance angiography with MS-325 (Gadofosveset),” Medical Science Monitor, vol. 13, no. 11, pp. CR469–CR474, 2007. View at Google Scholar · View at Scopus
  8. C. Klein, S. Schalla, B. Schnackenburg et al., “Improvement of image quality of non-invasive coronary artery imaging with magnetic resonance by the use of the intravascular contrast agent Clariscan (NC100150 injection) in patients with coronary artery disease,” Journal of Magnetic Resonance Imaging, vol. 17, no. 6, pp. 656–662, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. J. Schwitter, M. Saeed, M. F. Wendland et al., “Influence of severity of myocardial injury on distribution of macromolecules: extravascular versus intravascular gadolinium-based magnetic resonance contrast agents,” Journal of the American College of Cardiology, vol. 30, no. 4, pp. 1086–1094, 1997. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Flacke, J. S. Allen, J. M. Chia et al., “Characterization of viable and nonviable myocardium at MR imaging: comparison of gadolinium-based extracellular and blood pool contrast materials versus manganese-based contrast materials in a rat myocardial infarction model,” Radiology, vol. 226, no. 3, pp. 731–738, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. M. Dewey, N. Kaufels, M. Laule et al., “Magnetic resonance imaging of myocardial perfusion and viability using a blood pool contrast agent,” Investigative Radiology, vol. 39, no. 8, pp. 498–505, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Kelle, S. D. Roes, C. Klein et al., “Prognostic value of myocardial infarct size and contractile reserve using magnetic resonance imaging,” Journal of the American College of Cardiology, vol. 54, no. 19, pp. 1770–1777, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. S. D. Roes, S. Kelle, T. A. M. Kaandorp et al., “Comparison of myocardial infarct size assessed with contrast-enhanced magnetic resonance imaging and left ventricular function and volumes to predict mortality in patients with healed myocardial infarction,” American Journal of Cardiology, vol. 100, no. 6, pp. 930–936, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. E. Wellnhofer, A. Olariu, C. Klein et al., “Magnetic resonance low-dose dobutamine test is superior to scar quantification for the prediction of functional recovery,” Circulation, vol. 109, no. 18, pp. 2172–2174, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. R. J. Gibbons, U. S. Valeti, P. A. Araoz, and A. S. Jaffe, “The quantification of infarct size,” Journal of the American College of Cardiology, vol. 44, no. 8, pp. 1533–1542, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. R. J. Kim, D. S. Fieno, T. B. Parrish et al., “Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function,” Circulation, vol. 100, no. 19, pp. 1992–2002, 1999. View at Google Scholar · View at Scopus
  17. R. J. Kim, E. Wu, A. Rafael et al., “The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction,” New England Journal of Medicine, vol. 343, no. 20, pp. 1445–1453, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. H. Thiele, M. J. E. Kappl, S. Conradi, J. Niebauer, R. Hambrecht, and G. Schuler, “Reproducibility of chronic and acute infarct size measurement by delayed enhancement-magnetic resonance imaging,” Journal of the American College of Cardiology, vol. 47, no. 8, pp. 1641–1645, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. P. Caravan, N. J. Cloutier, M. T. Greenfield et al., “The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates,” Journal of the American Chemical Society, vol. 124, no. 12, pp. 3152–3162, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. D. C. Look and D. R. Locker, “Time saving in measurement of NMR and EPR relaxation times,” Review of Scientific Instruments, vol. 41, no. 2, pp. 250–251, 1970. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Baierl, M. Seiderer, S. Heywang, and M. Rath, “The contrast to noise ratio as a measure of tissue contrast in nuclear magnetic resonance tomography,” Digitale Bilddiagnostik, vol. 6, no. 3, pp. 101–110, 1986. View at Google Scholar · View at Scopus
  22. L. J. M. Kroft, J. Doornbos, R. J. van der Geest, and A. de Roos, “Blood pool contrast agent CMD-A2-Gd-DOTA-enhanced MR imaging of infarcted myocardium in pigs,” Journal of Magnetic Resonance Imaging, vol. 10, no. 2, pp. 170–177, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. O. Grebe, I. Paetsch, H. A. Kestler et al., “Optimal acquisition parameters for contrast enhanced magnetic resonance imaging after chronic myocardial infarction,” Journal of Cardiovascular Magnetic Resonance, vol. 5, no. 4, pp. 575–587, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. S. J. Flacke, S. E. Fischer, and C. H. Lorenz, “Measurement of the gadopentetate dimeglumine partition coefficient in human myocardium in vivo: normal distribution and elevation in acute and chronic infarction,” Radiology, vol. 218, no. 3, pp. 703–710, 2001. View at Google Scholar · View at Scopus
  25. J. N. Oshinski, Z. Yang, J. R. Jones, J. F. Mata, and B. A. French, “Imaging time after Gd-DTPA injection is critical in using delayed enhancement to determine infarct size accurately with magnetic resonance imaging,” Circulation, vol. 104, no. 23, pp. 2838–2842, 2001. View at Google Scholar · View at Scopus
  26. M. Saeed, O. Weber, R. Lee et al., “Discrimination of myocardial acute and chronic (scar) infarctions on delayed contrast enhanced magnetic resonance imaging with intravascular magnetic resonance contrast media,” Journal of the American College of Cardiology, vol. 48, no. 10, pp. 1961–1968, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. S. Gaillard, C. Kubiak, C. Stolz, B. Bonnemain, and D. Chassard, “Safety and pharmacokinetics of P792, a new blood-pool agent: results of clinical testing in nonpatient volunteers,” Investigative Radiology, vol. 37, no. 4, pp. 161–166, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Port, C. Corot, X. Violas, P. Robert, I. Raynal, and G. Gagneur, “How to compare the efficiency of albumin-bound and nonalbumin-bound contrast agents in vivo: the concept of dynamic relaxivity,” Investigative Radiology, vol. 40, no. 9, pp. 565–573, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. L. J. M. Kroft and A. de Roos, “Blood pool contrast agents for cardiovascular MR imaging,” Journal of Magnetic Resonance Imaging, vol. 10, no. 3, pp. 395–403, 1999. View at Publisher · View at Google Scholar · View at Scopus